KA
Therapeutic Areas
IMUNON Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IMNN-001 (TheraPlas™-IL-12) | Advanced Ovarian Cancer (Epithelial Ovarian Cancer) | Phase 2 |
| PlaCCine Platform | Infectious Diseases (SARS-CoV-2 validation) | Pre-clinical |
Leadership Team at IMUNON
SR
Stacy R. Lindborg
President, Chief Executive Officer & Board Director
DV
Douglas V. Faller
Chief Medical Officer
JW
Jeffrey W. Church
Interim Chief Financial Officer
SH
Sebastien Hazard
Executive Vice President & Chief Medical Officer
KL
Kristin Longobardi
Senior Vice President, Strategic Operations
SE
Susan Eylward
General Counsel & Corporate Secretary
MH
Michael H. Tardugno
Board of Directors
FJ
Frederick J. Fritz
Board of Directors
DB
Donald Braun
Board of Directors
CP
Christine Pellizzari
Board of Directors